SCHEMBL30718495

SCHEMBL30718495

Cc1noc(C)c1-c1ccc2sc(NC(=O)[C@H]3CCNC3)nc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 8/20 0.45
▸ RAB9A P51151 3/20 0.44
▸ BRD4 O60885 4/20 0.43
▸ BRD2 P25440 3/20 0.43
▸ BRD3 Q15059 3/20 0.43
▸ MAP4K1 Q92918 1/20 0.43
▸ MEN1 O00255 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ SNCA P37840 1/20 0.41
▸ DYRK1A Q13627 1/20 0.41
▸ KIT P10721 1/20 0.41
▸ PDGFRA P16234 1/20 0.41
▸ USP2 O75604 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ HIF1A Q16665 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31420243 0.85 ABL1 (0.52) ABL1MAP4K1SNCADYRK1AKIT
SCHEMBL31420215 0.85 ABL1 (0.52) ABL1MAP4K1SNCADYRK1AKIT
SCHEMBL17631568 0.85 NPC1 (0.43) ABL1RAB9AMEN1MAPTKMT2A
SCHEMBL17631569 0.85 NPC1 (0.43) ABL1RAB9AMEN1MAPTKMT2A
SCHEMBL17632001 0.81 NPC1 (0.42) ABL1RAB9AMEN1MAPTKMT2A
SCHEMBL30271964 0.81 NPC1 (0.42) ABL1RAB9AMEN1MAPTKMT2A
SCHEMBL17631999 0.81 NPC1 (0.42) ABL1RAB9AMEN1MAPTKMT2A
SCHEMBL30248327 0.81 KMT2A (0.47) ABL1RAB9AMEN1MAPTKMT2A
SCHEMBL30248351 0.81 RAB9A (0.42) ABL1RAB9AMEN1MAPTKMT2A
SCHEMBL30718469 0.81 RAB9A (0.42) ABL1RAB9AMEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4547247-A2 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF Dana-Farber Cancer Institute, Inc. (US) 2025-05-07 — — EP disclosed
WO-2024006956-A9 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-04-11 — — WO disclosed
WO-2024006956-A2 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-01-04 — — WO disclosed
Send feedback